$FOSUN PHARMA (02196.HK)$According to the announcement, on December 19, 2022, Fosun Industrial (Hong Kong) Co., Ltd., a subsidiary of the company, received the "Certificate of Registration of drugs / products" (as a subsidiary of Shanghai Fosun Pharmaceutical Industry). Based on the introduction of the mRNA COVID-19 vaccine BNT162b2 ("Fubitai BNT162b2") and the original / Omicron mutant BA.4-5 bivalent vaccine ("Fubitai bivalent vaccine") (collectively referred to as "these vaccines") have been officially registered as Hong Kong Special Administrative region of China (Hong Kong, China) drugs / products (biological products), of which Fubitai BNT162b2 is registered for basic immunization for people aged 12 and above, and Fubitai bivalent vaccine is registered for enhanced vaccination for people aged 12 and above.

The official registration of these vaccines in Hong Kong, China is in accordance with Chapter 138 of the laws of Hong Kong, China. After this registration, people who wish to be vaccinated can receive these vaccines at a medical institution or clinic in Hong Kong, China, on the basis of a local doctor's prescription (the scope of use will no longer be limited to vaccination under the local government vaccination program).

Prior to this, Fubitai BNT162b2, related dosage forms for children (for children aged 5 to 11 years) and infant dosage forms (for children aged 6 months to 4 years), and Fubitai bivalent vaccine have been approved for emergency use in Hong Kong, China (EUA) for local government vaccination programs respectively. And has been specially authorized by the Macao Special Administrative region of China ("Macao") to import for local government vaccination programs (among which BNT162b2 has also been approved as a routine imported vaccine, which can be prescribed by local doctors at medical institutions or clinics in Macau, China).